Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

Recruiting now

Conditions studied: Childhood ALL

In brief

The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.

Key facts

Study ID

NCT04794296

Run by

French Africa Pediatric Oncology Group

People needed

500

Starts

2021-11-15

Expected to finish

2030-12-31

Last updated by the study team

2026-03-02

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2

You may not qualify if…

• ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21

Where it is running

• CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (enrolling)
• CHU Donka 030 BP 554 — Conakry, Guinea (enrolling)
• Hôpital Aristide Le Dantec, Avenue Pasteur, — Dakar, Senegal (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.